Voyager Therapeutics Inc. (VYGR)
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Voyager Therapeutics, Inc.'s TRACER platform shows strong preclinical results for BBB-crossing gene therapies, securing multi-billion dollar deals with Novartis and Neurocrine, but lacks clinical trial data. VY7523, a monoclonal antibody for early Alzheimer's treatment, is expected to yield Phase I results by mid-2025, with potential undervaluation of VYGR shares. The competitive landscape includes Denali, Roche, and AbbVie, with varying BBB-crossing strategies, highlighting the speculative nature of investing in early-stage neurological therapies.
What Makes Voyager Therapeutics (VYGR) a New Buy Stock
Voyager Therapeutics (VYGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 152.5% in Voyager Therapeutics (VYGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wedbush upgrades Voyager to Outperform on pipeline progress
Wedbush upgraded Voyager Therapeutics to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company's tau antibody for Alzheimer's disease program and the AAV-mediated siRNA program for amyotrophic lateral sclerosis caused by mutations in the SOD1 gene into its valuation. Voyager's clinical and preclinical data that became available recently should allow for improved visibility into potential clinical outcomes for both programs, the analyst tells investors in a research note. With the pipeline moving forward closer to clinical entries and data readouts, and the shares trading near 52-week low, Wedbush believes Voyager represents an attractive investment opportunity "for investors with patience that are willing to tolerate the high risks associated with early stage clinical programs for neurodegenerative disorders."
Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript
Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q3 2024 Results Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief Executive Officer Toby Ferguson - Chief Medical Officer Todd Carter - Chief Scientific Officer Nathan Jorgensen - Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Jack Allen - Robert W. Baird Joon Lee - Truist Securities Jay Olson - Oppenheimer & Co. Lili Nsongo - Leerink Partners Patrick Trucchio - HC Wainwright Operator Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2024 Financial Results Conference Call.
Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.59 per share a year ago.
Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects
Voyager Therapeutics, Inc. initial safety and PK data from the phase 1a study using VY7523 for the treatment of patients with Alzheimer's Disease expected 1st half of 2025. Targeting the C-terminal for AD patients instead of N-terminal domain could end up resulting in a significantly greater reduction of tau protein. The global Alzheimer's Disease Therapeutics market is expected to reach $30.8 billion by 2033.
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.51 per share a year ago.
Equities Analysts Set Expectations for Voyager Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:VYGR)
Voyager Therapeutics, Inc. (NASDAQ:VYGR – Free Report) – Analysts at HC Wainwright increased their Q2 2024 EPS estimates for shares of Voyager Therapeutics in a research report issued on Thursday, May 16th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.31) for the quarter, up from their previous forecast of ($0.32). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.13) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.24) EPS. A number of other equities analysts also recently issued reports on VYGR. Guggenheim initiated coverage on shares of Voyager Therapeutics in a research note on Tuesday, March 26th. They set a “buy” rating and a $22.00 price objective on the stock. Citigroup initiated coverage on shares of Voyager Therapeutics in a research note on Thursday, March 7th. They issued a “buy” rating and a $16.00 target price for the company. Wedbush cut their price objective on Voyager Therapeutics from $10.00 to $8.00 and set a “neutral” rating on the stock in a report on Tuesday, May 14th. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Finally, Oppenheimer restated an “outperform” rating and set a $18.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday, May 15th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.00. Check Out Our Latest Analysis on VYGR Voyager Therapeutics Trading Down 2.3 % Shares of VYGR stock opened at $8.43 on Monday. Voyager Therapeutics has a twelve month low of $6.06 and a twelve month high of $14.34. The stock has a fifty day simple moving average of $8.75 and a two-hundred day simple moving average of $8.13. The stock has a market capitalization of $458.54 million, a price-to-earnings ratio of -168.60 and a beta of 0.98. Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a negative net margin of 2.56% and a negative return on equity of 1.28%. The firm had revenue of $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. Institutional Trading of Voyager Therapeutics A number of hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC raised its position in shares of Voyager Therapeutics by 1.4% in the fourth quarter. Armistice Capital LLC now owns 4,236,000 shares of the company’s stock worth $35,752,000 after acquiring an additional 58,000 shares during the period. Vanguard Group Inc. grew its holdings in Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after purchasing an additional 702,030 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Voyager Therapeutics by 3.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after buying an additional 37,144 shares in the last quarter. Acadian Asset Management LLC grew its stake in Voyager Therapeutics by 10.1% in the 1st quarter. Acadian Asset Management LLC now owns 459,850 shares of the company’s stock valued at $4,280,000 after acquiring an additional 42,029 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Voyager Therapeutics by 0.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 192,869 shares of the company’s stock worth $1,495,000 after acquiring an additional 1,455 shares in the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors. Voyager Therapeutics Company Profile (Get Free Report) Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
